Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
January 05 2017 - 7:30AM
Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated
to identifying, developing and commercializing innovative,
differentiated therapies to improve the lives of patients with
dermatologic diseases, today announced the appointment of Lori
Lyons-Williams as Chief Commercial Officer. In this new role, Lori
will be responsible for developing and implementing the commercial
strategy for Dermira’s Phase 3 product candidates: CIMZIA®
(certolizumab pegol), in development in collaboration with UCB
Pharma S.A. as a treatment for moderate-to-severe chronic plaque
psoriasis; DRM04, in development for the treatment of primary
axillary hyperhidrosis (excessive underarm sweating); and
olumacostat glasaretil (formerly DRM01), in development for acne
vulgaris.
“I am thrilled that Lori has joined Dermira at an important
time, as we begin to transition from a company solely focused on
product development to one preparing to commercialize three
products,” said Tom Wiggans, chairman and chief executive officer
of Dermira. “Lori is a well-regarded and respected sales and
marketing professional who has excelled at every level throughout
her career. Her experience working on highly successful dermatology
brands and in building a fully integrated commercial team makes her
particularly well-suited to bring what we believe is an exciting
portfolio of products to healthcare professionals and their
patients.”
Lori brings nearly 19 years of commercial experience to Dermira.
Prior to joining Dermira, she spent 15 years in positions of
increasing responsibility within the sales and marketing
organization at Allergan, most recently as Vice President, Sales
& Marketing for the Urology franchise. In this role, she helped
to build what ultimately became one of Allergan’s fastest growing
business units, and served as a member of the Allergan Commercial
Leadership Team as well as the Operational Leadership Team. In
previous roles within Allergan, she served as Product Director for
Allergan’s medical dermatology brands and also held senior-level
positions on the ACZONE® and BOTOX® marketing teams. Lori began her
career at Johnson & Johnson as a pharmaceutical sales
representative.
“I am delighted to be joining an organization with an
experienced leadership team and three promising late-stage
candidates that could one day potentially provide meaningful
clinical benefit to millions of patients with dermatologic
conditions,” said Lyons-Williams. “Dermira’s innovative approach,
commitment to differentiation, and dedication to foster scientific
advancement in dermatological conditions is refreshing. I am eager
to play a role in generating commercial successes and excited to
build a best-in-class team.”
Lori holds a BA in Interdisciplinary Studies from Virginia Tech
and an MBA from the Carlson School of Management of the University
of Minnesota.
About DermiraDermira is a biopharmaceutical
company dedicated to identifying, developing and commercializing
innovative, differentiated therapies to improve the lives of
patients with dermatologic diseases. Dermira’s portfolio includes
three Phase 3 product candidates that target significant unmet
needs and market opportunities: CIMZIA® (certolizumab pegol), in
development in collaboration with UCB Pharma S.A. for the treatment
of moderate-to-severe chronic plaque psoriasis; DRM04, in
development for the treatment of primary axillary hyperhidrosis
(excessive underarm sweating); and olumacostat glasaretil, in
development for the treatment of acne vulgaris. Dermira is
headquartered in Menlo Park, California. For more information,
please visit www.dermira.com.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com) and LinkedIn
page (https://www.linkedin.com/company/dermira-inc-) as channels of
distribution of information about its company, product candidates,
planned financial and other announcements, attendance at
upcoming investor and industry conferences and other matters. Such
information may be deemed material information and Dermira may use
these channels to comply with its disclosure obligations under
Regulation FD. Therefore, investors should monitor Dermira’s
website and LinkedIn page in addition to following its SEC filings,
press releases, public conference calls and webcasts.
Forward-Looking StatementsThe information in
this press release contains forward-looking statements and
information within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, which are subject to the “safe harbor” created
by those sections. This press release contains forward-looking
statements that involve substantial risks and uncertainties,
including statements with respect to Dermira’s potential
commercialization of its product candidates; Dermira’s ability to
bring its portfolio of products to healthcare professionals and
their patients and to potentially provide meaningful clinical
benefit to millions of patients with dermatologic conditions;
Dermira’s anticipated commercial efforts and successes; and the
building of a best-in-class team. These statements deal with future
events and involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements
to be materially different from the information expressed or
implied by these forward-looking statements. Factors that could
cause actual results to differ materially include risks and
uncertainties such as those relating to the design, implementation
and outcomes of Dermira’s clinical trials; the outcomes of
Dermira’s future meetings with regulatory agencies; Dermira’s
dependence on third-party clinical research organizations,
manufacturers and suppliers; Dermira’s ability to attract and
retain key employees; Dermira’s ability to obtain necessary
additional capital; and Dermira’s ability to continue to stay in
compliance with applicable laws and regulations. You should refer
to the section entitled “Risk Factors” set forth in Dermira’s
Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form
10-Q and other filings Dermira makes with the SEC from time to time
for a discussion of important factors that may cause actual results
to differ materially from those expressed or implied by Dermira’s
forward-looking statements. Furthermore, such forward-looking
statements speak only as of the date of this press release. Dermira
undertakes no obligation to publicly update any forward-looking
statements or reasons why actual results might differ, whether as a
result of new information, future events or otherwise, except as
required by law.
Contacts:
Media:
Erica Jefferson
Senior Director, Head of Corporate Communications
650-421-7216
erica.jefferson@dermira.com
Investors:
Andrew Guggenhime
Chief Operating Officer and Chief Financial Officer
650-421-7200
investors@dermira.com
Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
robert.uhl@westwicke.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Apr 2023 to Apr 2024